SIP
AKBA icon

Stoneridge Investment Partners’s Akebia Therapeutics AKBA Stock Holding History

Stoneridge Investment Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-30,263
Closed -$273K – 279
2016
Q1 		$273K Buy
30,263
+10,922
+56% +$88.6K 0.04% 247
2015
Q4 		$250K Sell
19,341
-14,065
-42% -$144K 0.03% 249
2015
Q3 		$323K Sell
33,406
-300
-0.9% -$2.75K 0.05% 236
2015
Q2 		$347K Buy
+33,706
New +$288K 0.04% 233

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Stoneridge Investment Partners's AKBA Position: Q2 2016 in Review

Stoneridge Investment Partners sold out of Akebia Therapeutics (AKBA) in Q2 2016, closing a stake of 30,263 shares — an estimated $273K sold.

Stoneridge Investment Partners first reported a position in AKBA in Q2 2015 and held it in 4 quarters. The position peaked at $347K in Q2 2015. 93 funds tracked by Wall St. Rank hold AKBA as of Q2 2016.

  • Stoneridge Investment Partners reported no remaining Akebia Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Stoneridge Investment Partners sold 30,263 Akebia Therapeutics shares in Q2 2016, an estimated $273K.
  • Stoneridge Investment Partners first reported a position in Akebia Therapeutics in Q2 2015 and held it in 4 quarters.
  • Stoneridge Investment Partners's Akebia Therapeutics position peaked at $347K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2016.

Based on Stoneridge Investment Partners's 13F filing for Q2 2016, filed 25 Jul 2016.